Samsung Biologics' $1.8B acquisition of PolyPeptide is a landmark move that positions the combined company as the dominant force in peptide-based drug manufacturing. PolyPeptide's 70-plus years of API heritage and booming GLP-1 pipeline — revenue up 41.6% in H1 2026 — make this a strategically sound deal at a 40% premium. This is exactly the kind of bold, large-scale investment that accelerates life-saving therapeutics to market faster.
The peptide industry's explosive growth is built on hype far outpacing hard science, with most trendy compounds jumping straight from animal studies to human use without rigorous trials. Consumers injecting unregulated peptide products have no guarantee of safety, accurate dosing or long-term effects. Pouring billions into scaling up peptide manufacturing before the evidence base catches up puts profits ahead of patient protection.
© 2026 Improve the News Foundation.
All rights reserved.
Version 7.4.1